<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04932876</url>
  </required_header>
  <id_info>
    <org_study_id>RESCOMUOI82152</org_study_id>
    <nct_id>NCT04932876</nct_id>
  </id_info>
  <brief_title>The Response of the Immune System of Patients With End Stage Kidney Disease on Dialysis and Kidney Transplant Recipients Vaccinated for COVID-19</brief_title>
  <official_title>Assessment of the Response of the Immune System of Patients With End Stage Kidney Disease on Dialysis and Kidney Transplant Recipients Vaccinated for COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Ioannina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Ioannina</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observational study of patients with End Stage Kidney Disease on dialysis and Kidney&#xD;
      Transplant Recipients, before and after vaccination for SARS-COV 2, after written consent,&#xD;
      with the aim of laboratory efficacy of the vaccine and safety regarding the clinical outcome&#xD;
      of patients and possible complications.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 24, 2021</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of the vaccine</measure>
    <time_frame>24 months</time_frame>
    <description>Humoral immune response to the vaccine as evaluated by generation of SARS-CoV-2 IgG II antibodies at two time points (before the second dose of the BNT162b2 vaccine and two weeks following the second dose of the BNT162b2 vaccine). Secondly, lympocyte subsets will be measured by flow cytometry (Naive and memeory T cells - CD45RO+, CD45 RA+, CD4+RO+, CD4+CDRA+, CD4+, CD8+, CD19+, NKT cells) at the two respective time points so as to assess alterations induced by vaccination. Serologic response will be estimated by measurement of anti SARS-CoV-2-spike IgGII titer (AU/ml) in the serum (using the ARCHITECT IgG II Quant test (Abbott); titers &gt;50 arbitrary units (AU)/ml are considered positive (detection range, 6.8-80,000 AU/ml); positive agreement, 99.4%; negative agreement, 99.6%).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complications caused by the vaccine</measure>
    <time_frame>24 months</time_frame>
    <description>Potential side effects associated with the vaccine shall be recorded. Percentages of lymphocytes subsets (as depicted before) in peripheral blood will be measured by flow cytometry. We will compare changes from baseline in the percentages of the lymphocytes subsets following the first and second dose of vaccination between the hemodialysis and kidney transplant recipeints group. In addition we will search for associations between percentages of lymphocytes subsets at diggerent measurement time points and antibody reponse.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>End Stage Kidney Disease</condition>
  <condition>Kidney Transplantion</condition>
  <condition>Covid19</condition>
  <condition>Vaccination</condition>
  <arm_group>
    <arm_group_label>ESKD - HD</arm_group_label>
    <description>End Stage Kidney Disease on Long Term Dialysis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KTR</arm_group_label>
    <description>Kidney Transplant Recipient</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SARS - COV 2 VACCINE</intervention_name>
    <description>Vaccination for SARS - COV 2</description>
    <arm_group_label>ESKD - HD</arm_group_label>
    <arm_group_label>KTR</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        End Stage Kidney Disease and Kidney Transplant Recipients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;18 years&#xD;
&#xD;
          -  Covid 19 vaccination&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  previous covid infection&#xD;
&#xD;
          -  recent infection&#xD;
&#xD;
          -  chronic infection&#xD;
&#xD;
          -  HBV, HCV, HIV&#xD;
&#xD;
          -  Active malignancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Evangelia Ntounousi, PHD</last_name>
    <phone>+302651007429</phone>
    <email>edounous@uoi.gr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Evangelia Ntounousi</name>
      <address>
        <city>Ioannina</city>
        <state>Epirus</state>
        <zip>45110</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evangelia Ntounousi, PHD</last_name>
      <email>edounous@uoi.gr</email>
    </contact>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 19, 2021</study_first_submitted>
  <study_first_submitted_qc>June 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2021</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Ioannina</investigator_affiliation>
    <investigator_full_name>Evangelia Ntounousi</investigator_full_name>
    <investigator_title>Assistant Professor Of Nephrology</investigator_title>
  </responsible_party>
  <keyword>End Stage Kidney Disease</keyword>
  <keyword>Kindey Trasplantation</keyword>
  <keyword>Immune System</keyword>
  <keyword>Covid19 Vaccination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

